Investors Relieved As Mylan Settlement Avoids Investigation

Mylan shares rallied on Oct. 7 following the company’s late-day Oct. 10 announcement that it agreed to settlement terms with the Department of Justice related to Epipen rebates for Medicaid prescriptions, but separate investigations and competition are looming.

chess

The ink is not dry on Mylan NV’s settlement with the US Department of Justice (DOJ) regarding EpiPen (epinephrine) rebates to Medicaid – and, in fact, the agreement still is being written – but investors are relieved that the company has avoided a major investigation and a larger penalty, despite lingering risks.

Mylan’s stock jumped 8.2% to close at $38.87 per share on Oct. 10 following the company’s announcement after the stock...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip